


PEG2000-C-DMG

Cat. No.:	HY-145411
Molecular Formula:	C ₁₃₄ H ₂₄₉ NO ₅₂
Molecular Weight:	2706.38
Target:	Others
Pathway:	Others
Storage:	-20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (36.95 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	0.3695 mL	1.8475 mL	3.6950 mL
		5 mM	0.0739 mL	0.3695 mL	0.7390 mL
	10 mM	0.0369 mL	0.1847 mL	0.3695 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (0.92 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (0.92 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (0.92 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	PEG2000-C-DMG, a lipid, can be used for the preparation of Onpattro. Onpattro, a hepatically directed investigational RNAi therapeutic agent, harnesses this process to reduce the production of mutant and wild-type transthyretin by targeting the 3' untranslated region of transthyretin mRNA ^{[1][2]} .
--------------------	---

REFERENCES

[1]. Garber K. Alnylam launches era of RNAi drugs. Nat Biotechnol. 2018;36(9):777-778.

Caution: Product has not been fully validated for medical applications. For research use only.